Apremilast

🧮 Dose calculator

Psoriasis and steroid-responsive dermatoses · Regimen source: FDA Otezla · 2.1

• • Days 1–5 titration per label Table 1 (from 10 mg in the morning) to reduce GI effects. Severe renal impairment: 30 mg once daily. FDA Otezla · 2.1FDA Otezla · 2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Otezla · 8.1

  “Risk Summary Available data with OTEZLA use in pregnant women have not identified a drug-associated risk of major birth defects or adverse maternal or fetal outcomes (see Data ) .”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Otezla · 8.2

  “Risk Summary There are no data on the presence of apremilast in human milk, its effects on the breastfed infant, or its effects on milk production.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Otezla · 8.4

  “OTEZLA Plaque Psoriasis The safety and effectiveness of OTEZLA have been established in pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Otezla · 8.5

  “… om severe diarrhea, nausea, or vomiting, monitor geriatric patients closely for such complications [see Warnings and Precautions (5.2) ] .”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.